- Previous Close
0.7600 - Open
0.7700 - Bid 0.7100 x --
- Ask 0.7200 x --
- Day's Range
0.6900 - 0.7700 - 52 Week Range
0.6900 - 2.0800 - Volume
85,167 - Avg. Volume
109,041 - Market Cap (intraday)
61.359M - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.69
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
oncolyticsbiotech.comRecent News: ONC.TO
View MorePerformance Overview: ONC.TO
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONC.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONC.TO
View MoreValuation Measures
Market Cap
65.68M
Enterprise Value
50.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.98
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-74.11%
Return on Equity (ttm)
-189.05%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.71M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
15.94M
Total Debt/Equity (mrq)
17.78%
Levered Free Cash Flow (ttm)
-16.34M